Lung Cancer clinical trials in Vermont

9 actively recruiting lung cancer trials at 5 sites across Vermont.

Data from ClinicalTrials.gov · last refreshed 2026-04-20

Phase 2, Phase 3 Recruiting Network

Lung-MAP: A Master Screening Protocol for Previously-Treated Non-Small Cell Lung Cancer

This screening and multi-sub-study randomized phase II/III trial will establish a method for genomic screening of similar large cancer populations followed by assigning and accruing simultaneously to a multi-sub-study hybrid Master Protoco…

Sponsor: SWOG Cancer Research Network

NCT ID: NCT03851445

Sites in Vermont:

Central Vermont Medical Center/National Life Cancer Treatment — Berlin Corners, Vermont
University of Vermont Medical Center — Burlington, Vermont
University of Vermont and State Agricultural College — Burlington, Vermont
Dartmouth Cancer Center - North — Saint Johnsbury, Vermont
White River Junction Veteran Administration Medical Center — White River Junction, Vermont

View on ClinicalTrials.gov →

Phase 2, Phase 3 Recruiting NIH

Testing the Addition of Radiation Therapy to the Usual Immune Therapy Treatment (Atezolizumab) for Extensive Stage Small Cell Lung Cancer, The RAPTOR Trial

This phase II/III trial compares the effect of adding radiation therapy to the usual maintenance therapy with atezolizumab versus atezolizumab alone in patients who have already received atezolizumab plus chemotherapy for the treatment of …

Sponsor: National Cancer Institute (NCI)

NCT ID: NCT04402788

Sites in Vermont:

Central Vermont Medical Center/National Life Cancer Treatment — Berlin Corners, Vermont
University of Vermont Medical Center — Burlington, Vermont
University of Vermont and State Agricultural College — Burlington, Vermont
Dartmouth Cancer Center - North — Saint Johnsbury, Vermont

View on ClinicalTrials.gov →

Phase 3 Recruiting Academic/Other

Comparing Impact of Treatment Before or After Surgery in Patients With Stage II-IIIB Resectable Non-small Cell Lung Cancer

This phase III trial compares standard therapy given after surgery (adjuvant) to standard therapy given before and after surgery (perioperative) in treating patients with stage II-IIIB non-small cell lung cancer (NSCLC) that can be removed…

Sponsor: Alliance for Clinical Trials in Oncology

NCT ID: NCT06632327

Sites in Vermont:

Dartmouth Cancer Center - North — Saint Johnsbury, Vermont

View on ClinicalTrials.gov →

Phase 3 Recruiting Network

Thoracotomy Versus Thoracoscopic Management of Pulmonary Metastases in Patients With Osteosarcoma

This phase III trial compares the effect of open thoracic surgery (thoracotomy) to thoracoscopic surgery (video-assisted thoracoscopic surgery or VATS) in treating patients with osteosarcoma that has spread to the lung (pulmonary metastase…

Sponsor: Children's Oncology Group

NCT ID: NCT05235165

Sites in Vermont:

University of Vermont and State Agricultural College — Burlington, Vermont

View on ClinicalTrials.gov →

Phase 3 Recruiting Industry

Study of Olomorasib (LY3537982) in Combination With Standard of Care in Participants With Resected or Unresectable KRAS G12C-mutant Non-Small Cell Lung Cancer

The main purpose of this study is to assess if olomorasib in combination with pembrolizumab is more effective than the pembrolizumab and placebo combination in part A in participants with resected KRAS G12C-mutant NSCLC and to assess if ol…

Sponsor: Eli Lilly and Company

NCT ID: NCT06890598

Sites in Vermont:

The University of Vermont Medical Center Inc. — Burlington, Vermont

View on ClinicalTrials.gov →

Phase 2 Recruiting Network

Comparing Combinations of Targeted Drugs for Advanced Non-Small Cell Lung Cancer That Has EGFR and MET Gene Changes (A Lung-MAP Treatment Trial)

This phase II Lung-MAP treatment trial test the combination of targeted drugs (capmatinib, osimertinib, and/or ramucirumab) in treating patients with non-small cell lung cancer that may have spread from where it first started to nearby tis…

Sponsor: SWOG Cancer Research Network

NCT ID: NCT05642572

Sites in Vermont:

Central Vermont Medical Center/National Life Cancer Treatment — Berlin Corners, Vermont
University of Vermont Medical Center — Burlington, Vermont
University of Vermont and State Agricultural College — Burlington, Vermont

View on ClinicalTrials.gov →

Phase 2 Recruiting Industry

A Study of JNJ-90301900 in Combination With Chemoradiation Followed by Consolidation Immunotherapy for Non-Small Cell Lung Cancer (NSCLC)

The purpose of this study is to determine whether JNJ-90301900 added to concurrent platinum-based doublet chemotherapy with radiation therapy (cCRT) followed by consolidation immunotherapy (cIT) can improve objective response rate (ORR; th…

Sponsor: Johnson & Johnson Enterprise Innovation Inc.

NCT ID: NCT06667908

Sites in Vermont:

University of Vermont Medical Center — Burlington, Vermont

View on ClinicalTrials.gov →

Recruiting Academic/Other

Small Cell Lung Cancer Community Engagement to Eliminate Research Discepancies

This study will evaluate if a direct-to-patient, de-centralized, remote approach will improve clinical research outreach and engagement for patients with SCLC, in the context of a bio-specimen collection study. The study will also assess s…

Sponsor: Addario Lung Cancer Medical Institute

NCT ID: NCT06486428

Sites in Vermont:

Https://Alcmi.Org/Clinical-Trials/Current-Studies/Succeed-Study.Html — Multiple Locations, Vermont

View on ClinicalTrials.gov →

NA Recruiting Academic/Other

Accelerated Pulmonary Rehabilitation in the Preoperative Period

This proposed project will be a single arm, non-masked study. Participants who are actively smoking with a diagnosis of a new lung nodule, either confirmed or suspicious for lung cancer, with a plan for lung cancer treatment with or withou…

Sponsor: University of Vermont

NCT ID: NCT06432972

Sites in Vermont:

University of Vermont Medical Center — Burlington, Vermont

View on ClinicalTrials.gov →

Medical disclaimer: This page aggregates public ClinicalTrials.gov data. It is not medical advice. Always confirm eligibility and enrollment details with the trial site or your oncologist.

Source: ClinicalTrials.gov API v2 · Last checked: 2026-04-20